Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

Inclusion Criteria

• •Adult participants, male or female patients ≥ 18 years old at index date
• •Participants must voluntarily give written informed consent form (ICF). Patients must read and fully understand the ICF
• •Participants with confirmed diagnosis of RMS at index date, diagnosed by the treating physician according to applicable clinical practice guidelines (currently McDonald 2017 criteria), with high disease activity.
• •Required historical data should be available: number of relapses in the 12 months prior to index date, DMTs taken prior to index date, date of MS diagnosis, and data of at least 1 MRI prior to index date as specified in the drug Summary of Product Characteristics (SmPC)
• •Fulfillment of the indication for treatment with cladribine tablets at index date, per standard of care in accordance with the local SmPC
• •Meeting 1 of the following criteria:
• •* Prospective participants: Having been prescribed with cladribine tablets or having taken at least one dose of cladribine tablets, with enrollment date prior to the second treatment week
• •* Retrospective participants: Having taken at least one dose of cladribine tablets, with enrollment date during or after the second treatment week but not more than 3 years after the first dose of cladribine tablets